Use of anti-M. leprae phenolic glycolipid-I antibody detection for early diagnosis and prognosis of XXXX .

@entity1 @entity1203 @entity4430 @entity4544 @entity1201
Untreated @entity1 suffering from @entity4544 , @entity1203 and indeterminate @entity1201 , their domiciliary contacts, and healthy controls, all living in Guadeloupe, West Indies, were tested by an ELISA for detecting IgM antibodies to the terminal disaccharide of the phenolic glycolipid-I antigen of @entity4430 . On most subjects, a Mitsuda test was also performed. A large majority of the @entity4544 @entity1 and healthy subjects were Mitsuda positive. The seropositivity rate reached 44% among @entity4544 @entity1 , and 6% among healthy subjects, with low antibody levels. @entity1203 @entity1 were all Mitsuda negative and seropositive, with antibody production varying from low levels, as seen in @entity4544 @entity1 , to much higher levels. Indeterminate @entity1201 @entity1 included 62% Mitsuda-positive subjects and 54% seropositive subjects with a large dispersion of antibody levels. Comparing the results of the Mitsuda test to those of the ELISA by factorial analysis allowed us to define several subgroups among this population: some (25%) showed a " @entity1203 -like" immune status (Mitsuda negative, seropositive); others (54%) exhibited " @entity4544 -like" profiles (Mitsuda positive without antibodies or with low antibody levels). " @entity1203 -like" cases were significantly older than " @entity4544 -like" @entity1 . A group of subjects (17%) was Mitsuda negative and seronegative, thus displaying a true "indeterminate" immune profile, which had not been seen in other forms of the disease and had been observed in only 2 out of 51 healthy controls. A large majority of contacts was Mitsuda positive, with 33% of them being seropositive, indicating that the prevalence of @entity4430 infection greatly exceeds that of overt @entity1201 in this population.(ABSTRACT TRUNCATED AT 250 WORDS)
